About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker ENTA · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 2, 2026A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With…
NCT07908381 · RSV
zelicapavir, Placebo
ENTA
Enanta Pharmaceuticals, Inc
Phase 2/3Recruiting860Jul 2029Registry ↗
Aug 19, 2026A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.
NCT05568706 · RSV Infection
EDP-938, Placebo
ENTA
Enanta Pharmaceuticals, Inc
Phase 2Completed187Jun 23, 2025Registry ↗
Jul 20, 2026A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days…
NCT07482657 · RSV Infection, RSV
zelicapavir, Placebo
ENTA
Enanta Pharmaceuticals, Inc
Phase 2Recruiting150Dec 2026Registry ↗
Apr 21, 2026A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single a…
NCT07540910 · Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
EDP-978, Placebo
ENTA
Enanta Pharmaceuticals, Inc
Phase 1Recruiting98Nov 2026Registry ↗
Oct 7, 2025A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus…
NCT06170242 · RSV Infection
EDP-323 Dose Regimen 1, EDP-323 Dose Regimen 2
ENTA
Enanta Pharmaceuticals, Inc
Phase 2Completed142Jun 17, 2024Registry ↗
Jul 28, 2025A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults
NCT06601192 · RSV Infection, QTc Interval
zelicapavir (therapeutic dose), zelicapavir (supratherapeut…
ENTA
Enanta Pharmaceuticals, Inc
Phase 1Completed72Feb 2, 2025Registry ↗
Jul 28, 2025A Study to Evaluate EDP 938 Regimens in Children With RSV
NCT04816721 · Respiratory Syncytial Virus (RSV)
EDP-938, Placebo
ENTA
Enanta Pharmaceuticals, Inc
Phase 2Completed99Aug 19, 2024Registry ↗
Jul 1, 2025A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin…
NCT06917508 · RSV Infection, Drug Drug Interaction
EDP-323, Midazolam
ENTA
Enanta Pharmaceuticals, Inc
Phase 1Completed24Jun 6, 2025Registry ↗
Jul 1, 2025A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and…
NCT06847464 · RSV Infection, Drug Drug Interaction (DDI)
EDP-323, Itraconazole
ENTA
Enanta Pharmaceuticals, Inc
Phase 1Completed48May 24, 2025Registry ↗
Aug 22, 2024Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial…
NCT04633187 · Respiratory Syncytial Virus Infections
EDP-938, Placebo
ENTA
Enanta Pharmaceuticals, Inc
Phase 2Terminated9May 31, 2023Registry ↗
Aug 19, 2024A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19
NCT05616728 · COVID-19
EDP-235, Placebo
ENTA
Enanta Pharmaceuticals, Inc
Phase 2Completed231Feb 8, 2023Registry ↗
Oct 30, 2023A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respira…
NCT04196101 · Respiratory Syncytial Virus
EDP-938, Placebo
ENTA
Enanta Pharmaceuticals, Inc
Phase 2Completed82Jan 4, 2022Registry ↗
Sep 1, 2023A Study of EDP-323 in Healthy Subjects
NCT05587478 · RSV Infection
EDP-323, Placebo
ENTA
Enanta Pharmaceuticals, Inc
Phase 1Completed82Mar 29, 2023Registry ↗
May 19, 2023A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Live…
NCT04378010 · Non-Alcoholic Steatohepatitis
EDP-305 1.5 mg, EDP-305 2 mg
ENTA
Enanta Pharmaceuticals, Inc
Phase 2Terminated98Oct 4, 2021Registry ↗
Apr 27, 2023Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjec…
NCT05594615 · COVID-19
EDP-235, Midazolam
ENTA
Enanta Pharmaceuticals, Inc
Phase 1Completed24Nov 4, 2022Registry ↗
Apr 27, 2023Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy S…
NCT05594602 · COVID-19
EDP-235, EDP-235
ENTA
Enanta Pharmaceuticals, Inc
Phase 1Completed36Dec 14, 2022Registry ↗
Aug 19, 2022A Study of EDP-235 in Healthy Subjects
NCT05246878 · SARS CoV 2 Infection
EDP-235, Placebo
ENTA
Enanta Pharmaceuticals, Inc
Phase 1Completed72Jul 20, 2022Registry ↗
May 3, 2022A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model
NCT03691623 · RSV Infection
EDP-938 Dose 1, EDP-938 Dose 2
ENTA
Enanta Pharmaceuticals, Inc
Phase 2Completed179Sep 30, 2019Registry ↗
Mar 23, 2022Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects
NCT04927793 · Respiratory Syncytial Virus (RSV)
EDP-938
ENTA
Enanta Pharmaceuticals, Inc
Phase 1Completed8Jul 4, 2021Registry ↗
Feb 14, 2022A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PA…
NCT04971512 · Chronic Hepatitis B Virus Infection
EDP-721, Placebo (Part 1)
ENTA
Enanta Pharmaceuticals, Inc
Phase 1Terminated26Dec 20, 2021Registry ↗
Jan 11, 2022A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Tr…
NCT04470388 · Chronic HBV Infection
EDP-514, Placebo
ENTA
Enanta Pharmaceuticals, Inc
Phase 1Completed25Aug 30, 2021Registry ↗
Jan 11, 2022A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infecti…
NCT04008004 · Chronic HBV Infection
EDP-514, Placebo
ENTA
Enanta Pharmaceuticals, Inc
Phase 1Completed99Jul 14, 2021Registry ↗
Oct 29, 2021A Study of EDP-297 in Healthy Subjects
NCT04559126 · NASH - Nonalcoholic Steatohepatitis With Liver Fibrosis
EDP-297, Placebo
ENTA
Enanta Pharmaceuticals, Inc
Phase 1Completed82Jun 21, 2021Registry ↗
Oct 13, 2021Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in…
NCT04498741 · RSV Infection
EDP-938, EDP-938
ENTA
Enanta Pharmaceuticals, Inc
Phase 1Completed89May 27, 2021Registry ↗
Sep 16, 2021A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects Wi…
NCT03421431 · Non-Alcoholic Steatohepatitis
EDP-305 Dose 1, EDP-305 Dose 2
ENTA
Enanta Pharmaceuticals, Inc
Phase 2Completed134Jun 14, 2019Registry ↗
Aug 16, 2021Drug-Drug Interaction Study Between EDP-514, Itraconazole, Carbamazepine, and Quinidine in Healthy…
NCT04783753 · Hepatitis B
EDP-514, EDP-514
ENTA
Enanta Pharmaceuticals, Inc
Phase 1Completed72Jun 28, 2021Registry ↗
May 18, 2021A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects Wi…
NCT03394924 · Primary Biliary Cholangitis
EDP-305 1 mg, EDP-305 2.5 mg
ENTA
Enanta Pharmaceuticals, Inc
Phase 2Completed68Dec 19, 2019Registry ↗
May 4, 2021Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects
NCT04871724 · RSV Infection
EDP-938, Fluconazole
ENTA
Enanta Pharmaceuticals, Inc
Phase 1Completed24Mar 30, 2021Registry ↗
Jul 24, 2019A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of…
NCT03783897 · NASH - Nonalcoholic Steatohepatitis
EDP-305, Oral Contraceptive
ENTA
Enanta Pharmaceuticals, Inc
Phase 1Completed43Jun 4, 2019Registry ↗
Jun 14, 2019Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subje…
NCT03755778 · RSV Infection
EDP-938, EDP-938
ENTA
Enanta Pharmaceuticals, Inc
Phase 1Completed72Jan 21, 2019Registry ↗
Feb 12, 2019Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects
NCT03750383 · RSV Infection
EDP-938, EDP-938
ENTA
Enanta Pharmaceuticals, Inc
Phase 1Completed48Nov 17, 2018Registry ↗
Dec 5, 2018Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers
NCT03610945 · NASH - Nonalcoholic Steatohepatitis
Fluconazole, Quinidine
ENTA
Enanta Pharmaceuticals, Inc
Phase 1Completed48Aug 15, 2018Registry ↗
Nov 21, 2018Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects
NCT03748628 · NASH - Nonalcoholic Steatohepatitis
EDP-305
ENTA
Enanta Pharmaceuticals, Inc
Phase 1Completed8Oct 13, 2018Registry ↗
Oct 10, 2018A Study of EDP-938 in Healthy Subjects
NCT03384823 · RSV Infection
EDP-938, Placebo
ENTA
Enanta Pharmaceuticals, Inc
Phase 1Completed90Jul 3, 2018Registry ↗
Nov 6, 2017Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers
NCT03213145 · NASH - Nonalcoholic Steatohepatitis
intraconazole, Rifampin
ENTA
Enanta Pharmaceuticals, Inc
Phase 1Completed48Aug 10, 2017Registry ↗
Nov 6, 2017A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healt…
NCT03207425 · NASH
EDP 305
ENTA
Enanta Pharmaceuticals, Inc
Phase 1Completed29Sep 16, 2017Registry ↗
Aug 21, 2017Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunt…
NCT03187496 · NASH
Midazolam, Caffeine
ENTA
Enanta Pharmaceuticals, Inc
Phase 1Completed24Jun 1, 2017Registry ↗
Aug 21, 2017A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD
NCT02918929 · Presumptive NAFLD
EDP 305, Placebo
ENTA
Enanta Pharmaceuticals, Inc
Phase 1Completed146Jun 2017Registry ↗
Jan 23, 2017EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients
NCT02652377 · Hepatitis C
EDP-494, Placebo
ENTA
Enanta Pharmaceuticals, Inc
Phase 1Completed100Dec 27, 2016Registry ↗
Jan 29, 2016Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects
NCT01856426 · Hepatitis C
EDP239, Placebo
ENTA
Enanta Pharmaceuticals, Inc
Phase 1Completed28Nov 2014Registry ↗
May 12, 2015Evaluation of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of EDP-788
NCT02255968 · Healthy
EDP-788, Placebo
ENTA
Enanta Pharmaceuticals, Inc
Phase 1Terminated16Oct 2014Registry ↗
Jan 9, 2015Two-way Interaction Between Alisporivir and EDP239
NCT02173574 · Hepatitis C Virus
DEB025, EDP239
ENTA
Enanta Pharmaceuticals, Inc
Phase 1Completed42Nov 2014Registry ↗
Jan 9, 2015Evaluation of the Safety and Pharmacokinetics of a Single Oral Dose of EDP-788
NCT01999725 · Safety in Normal Volunteers
EDP-788, Placebo
ENTA
Enanta Pharmaceuticals, Inc
Phase 1Completed80Sep 2014Registry ↗

43 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:05 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances